Cipla To Recalibrate US Investments
A More Measured Approach To US Generic R&D And Specialty
Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components – prescription, trade generic and consumer health – are being brought under a “single capital allocation framework.”
You may also be interested in...
After lower growth in its India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.
Ex-Torrent COO Arunesh Verma is to lead Cipla’s North America generics business, while the head of Cipla USA has been repositioned to lead the India prescription business, among other personnel changes.
Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.